GT Biopharma
GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company dedicated to the advancement of immunotherapy treatments for cancer and other serious diseases. By focusing on the limitations of existing treatments, GT Biopharma aims to provide innovative solutions that are both targeted and effective.
Products & Team
GTB-3650
GTB-3650 is a TriKE therapeutic agent specifically targeting CD33-expressing hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The product is designed to engage the patient’s immune cells to more effectively target and kill cancer cells, thereby enhancing the therapeutic prospects for patients with challenging forms of blood cancer.
GTB-3650 addresses the significant need for more effective treatments in patients suffering from difficult-to-treat blood cancers, particularly those who have poor responses to current therapies.
Patients face limited options with conventional therapies, often experiencing inadequate efficacy and significant side effects, which GT Biopharma seeks to mitigate through its innovative approaches.